Newmarket Scientific
Newmarket Scientific

NEWS: Biosensis Amyloid beta antibody - (clone MOAB-2) Improved formulation - Same clone, so why pay more!

The presence of aggregated amyloid-β peptides (Aβ) is one of the hallmarks of Alzheimer's Disease (AD). However, the form(s) of Aβ-peptides associated with this pathology remains unclear. In particular, the neurotoxicity of intraneuronal Aβ accumulation is an area of considerable controversy, principally because antibodies used in earlier work and thought to be specific for Aβ have been shown to also detect intraneuronal amyloid precursor protein (APP) and not Aβ exclusively.


Our monoclonal antibody to Amyloid beta peptide (Amyloid beta 40/42) from Biosensis (M-1586-100) is a new formulation of clone MOAB-2 (this clone is also known as Clone 6C3), a pan-specific monoclonal antibody to Amyloid beta residues 1-4. This new formulation provides clearer staining, stronger reactivity and greater sensitivity than formulations from other maufacturers and the Biosensis formulation of MOAB-2 is also the only one endorsed by the original developers.


Additionally, unlike other monoclonals such as 6E10 and 4G8, MOAB-2 does not cross react with APP or APP C-terminal fragments, making this monoclonal and this formulation truly the best available.



Immunohistochemical detection of Aβ and APP


Immunohistochemical detection of Aβ and APP in coronal sections of the frontal cortex of 1-month old 5xFAD mice. Sections were co-stained with M-1586-100 or APP antibodies (N-terminus and C-terminus). MOAB-2 staining was punctate and did not co-localize with either APP antibodies. Figure courtesy of Youmans et al (2012).




Related products:


Biosensis APP antibodies


Oligomeric Amyloid-beta ELISA Kits,


Amylo-Glo - Amyloid beta plaque staining solution